DEFB129: A Potential Drug Target and Biomarker for Diseases (G140881)

Target Name: DEFB129

NCBI ID: G140881

DEFB129

DEFB129: A Potential Drug Target and Biomarker for Diseases

DEFB129 (Beta-defensin 129) is a protein that is expressed in various tissues, including the brain, lungs, heart, kidneys, and intestines. It is a member of the defensin family, which includes proteins that play a crucial role in the immune response. The aim of this article is to discuss DEFB129 as a drug target and its potential as a biomarker for various diseases.

Beta-defensin 129 (DEFB129)

DEFB129 is a 129-kDa protein that is expressed in various tissues. It is synthesized in the liver and is predominantly expressed in the brain, where it is involved in the immune response. DEFB129 is a member of the defensin family, which includes proteins that play a crucial role in the immune response.

The defensin family of proteins consists of various isoforms, including defensin-1, -2, -3, and -4. These proteins are involved in various functions, including immune surveillance, inflammation, and tissue repair. DEFB129 is one of the isoforms of the defensin family that is expressed in the brain.

DEFB129 is involved in the immune response by regulating the movement of immune cells into the brain. It has been shown to interact with the immune cell receptor PD-L1, which is a negative regulator of immune responses. By interacting with PD-L1, DEFB129 has been shown to prevent the immune cells from reaching the brain, thereby modulating the immune response.

In addition to its role in the immune response, DEFB129 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of inflammation in various tissues, including the brain.

DEFB129 as a drug target

The potential use of DEFB129 as a drug target is based on its involvement in the immune response and inflammation. Several studies have shown that inhibiting the activity of DEFB129 can be effective in treating various diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

One of the potential mechanisms by which DEFB129 can be used as a drug target is by inhibiting its ability to interact with PD-L1. As mentioned earlier, PD-L1 is a negative regulator of immune responses and has been shown to play a role in the development of cancer. By inhibiting the activity of DEFB129, it may be possible to enhance the immune response and improve treatment outcomes in various diseases.

Another potential mechanism by which DEFB129 can be used as a drug target is by modulating the balance of immune cells in the body. The immune system is a complex system that involves the regulation of various immune cells, including T cells and B cells. By modulating the balance of these cells, it may be possible to improve immune function and reduce the risk of disease.

In addition to its potential as a drug target, DEFB129 has also been shown to be a valuable biomarker for various diseases. The immune response is a complex process that involves the production of various biomarkers, including cytokines and chemokines. By measuring the level of these biomarkers, it may be possible to assess the immune response and identify potential disease biomarkers.

In conclusion, DEFB129 is a protein that is involved in various functions in the immune response and inflammation. Its potential as a drug target is based on its ability to interact with PD-L1 and modulate the balance of immune cells. In addition to its potential as a drug target, DEFB129 has also been shown to be a valuable biomarker for various diseases. Further research is needed to fully understand the role of DEFB129

Protein Name: Defensin Beta 129

Functions: Has antibacterial activity

The "DEFB129 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB129 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets